Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + eribulin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Bevacizumab + eribulin is a combination therapy used primarily in the treatment of HER2-negative metastatic breast cancer. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. Eribulin is a synthetic analog of halichondrin B and acts as a microtubule dynamics inhibitor; it binds to the plus ends of microtubules, suppressing their polymerization and extension without affecting depolymerization, leading to cell cycle arrest at G2/M phase and apoptosis. This combination has been studied in both first-line and second-line settings for metastatic breast cancer patients who have progressed after prior therapies[1][2][3][6].
- Other names
- bevacizumab + eribulinAvastin + Halaven
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + eribulin.